Sinovac Biotech Ltd. (SVA) Posts Mixed Q3 Results; Reaffirms Outlook
Tweet Send to a FriendGet Alerts SVA Hot Sheet
Trade SVA Now!
Sinovac Biotech Ltd. (NYS: SVA) reports Q3 loss of $0.01, versus the analyst estimate of $0.02. Revenue for the quarter came in at $9.55 million, versus the consensus estimate of $9.53 million.
Reaffirms FY10 outlook.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Reaffirms FY10 outlook.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
- Destination Xl Grp (DXLG) Tops Q1 EPS by 1c; Comps Up 17.7%
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
